Abstract:
The invention is directed to a biocompatible polysaccharide derivative (I) which comprises (1) a polysaccharide covalently bonded to aspartic acid, (2) a two step process to prepare said material from a polysaccharide, maleic anhydride and ammonia, and (3) the use of these materials in a variety of technical applications, e.g. as components in soil and seed treatment compositions to provide enhanced seedling vigour and as drug delivery agents. Since the compounds (I) are only composed of natural materials (i.e. a polysaccharide and an aspartic acid), they are considered to be easily biodegradable.
Abstract:
Matrices formed from a natural biodegradable material and that exhibit surface degradation in the presence of an enzyme are described. Matrices including a bioactive agent can be implanted or formed in a subject for release of the bioactive agent upon degradation of the matrix. The matrix can be provided in various forms, including coatings for implantable devices, implants, and in-situ formed matrices. The matrix can also be in the form of a medical device having a structure that is used to treat a medical condition.
Abstract:
This invention describes improvements in or relating to the production of polysaccharide derivatives; more particularly it relates to a method of converting insoluble polysaccharides to a form in which they form part of an anhydrous system in which they may be used as chemical intermediates in the production of derivatives.
Abstract:
The invention concerns a process for the manufacture of an acylated polymer composition comprising amylose and/or amylopectin, comprising a pre-treatment step in the presence of an acid, a salt and a polycarboxylic acid, subsequent acylation and, preferably, a post-treatment step with an acid. The products obtained are useful as additives in inks, varnishes, lacquers, coatings, thickeners, adhesives or binders.
Abstract:
The invention relates to novel pharmaceutical forms for antibiotics containing amino sugar, amphotericin B, daunorubicin and doxorubicin, in which the known side effects are reduced and which can be used in a simple manner. The antimycotic agent B is nephrotoxic. The cytostatic agents daunorubicin and doxorubicin are highly cardiotoxic. The novel pharmaceutical forms are antibiotic-starch conjugates, wherein the antibiotic is combined with the polysaccharide at the reducing end thereof by means of a peptide bond. According to the invention, said bond is carried out by means of J2-oxidation of the starch derivative at the reducing end thereof in an aqueous alkaline solution, and by coupling the starch derivative oxidised thereby to the antibiotic in an organic solution. The conjugates obtained are less toxic. The polysaccharide part can be decomposed by serum- alpha -amylase and the peptide bond can be accessed by an enzymatic attack.
Abstract:
The invention concerns moisture-proof, thermoplastic, environmentally friendly, thermoplastically produced products and cast films of processable starch materials consisting of starchy fat acyl compounds obtainable from amylose-rich starches which dissolve with difficulty in water and softeners which, like citric acid ethyl ester, glycerin acetate and lactic acid ester, have a gelling effect and preferably have solution properties causing a brilliant transparency and are demonstrably bio-degradable.
Abstract:
Non-crosslinked derivatives of oligo/polysaccharides of formula I, wherein: X is OH, O M, NH-R 1 , O-R 1 ; M is an alkaline or alkaline-earth metal, transition metal, or cation containing a quaternary nitrogen atom; Y is H or R 2 ; R1: the residue of an oligo/polysaccharide; R2: the residue of a C1-C4 linear chain aliphatic carboxylic acid or citric acid; provided that at least one X is NH-R1 or O-R1, while the other two X are present in acid (OH) or salified form (OM).